Dr. Reddy's Laboratories Limited (DRREDDY) — Board Meeting | 24 October 2025(2 announcements)

· NSE 🟡 Notable Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
1 Board Meeting 🟡 Notable Neutral 📄 PDF

Dr. Reddy's Laboratories' board approved the assignment of Chief Human Resources Officer (CHRO) responsibilities to Mr. Sanjay Sharma, Global Head Operations, effective December 1, 2025, following the resignation of Ms. Archana Bhaskar (effective November 30, 2025). Sharma brings 34 years of experience across FMCG and pharmaceuticals sectors, with credentials including an IIT Delhi chemical engineering degree and Harvard Business School's Advanced Management Program. This consolidation replaces an external hire with internal promotion.

2 Board Meeting 🟡 Notable Neutral 📄 PDF

Dr. Reddy's Laboratories reported Q2 FY26 revenue of ₹88.1 billion (9.8% YoY growth) and H1 FY26 revenue of ₹173.5 billion (10.6% YoY growth). Net profit grew 14% YoY in Q2 to ₹14.3 billion and 8% YoY in H1 to ₹28.4 billion. Gross margins compressed by 492 basis points YoY due to Lenalidomide sales reduction and generic price erosion. The company acquired STUGERON brand for $50.5 million and launched multiple new products across markets. An ongoing FCPA investigation regarding alleged improper payments in Ukraine remains under SEC/DOJ engagement.

About Dr. Reddy's Laboratories Limited (DRREDDY)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,11,568.6 Cr P/E: 20.0 ROE: 16.6% ROCE: 19.7%

View full DRREDDY stock details →

📡 Get AI alerts when DRREDDY files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track DRREDDY — Free

📊 More DRREDDY filings

See all DRREDDY filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when DRREDDY files new disclosures

Track DRREDDY filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track DRREDDY — Free

Free account · 2 AI queries/day